Physician profile
Fazila Aslam
NPI 1316139561
$1,728.90
in general payments reported to CMS, 2019-2025
17 companies · $759 in 2025
The $759 reported for 2025 was more than what 75% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.62 · 2021: $159 · 2022: $51.85 · 2023: $190 · 2024: $483 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $496.47 | 2021-2025 | Teflaro |
| Merck Sharp & Dohme LLC | $367.75 | 2021-2025 | Zerbaxa, Dificid, Pifeltro |
| Gilead Sciences, INC. | $194.12 | 2024-2025 | Veklury, Biktarvy |
| Smith+Nephew, INC. | $117.98 | 2019-2024 | Collagenase Santyl |
| Aimmune Therapeutics, INC. | $85.50 | 2024-2025 | Vowst |
| Shionogi INC | $67.54 | 2024-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $60.83 | 2024-2025 | Nuzyra |
| Insmed, INC. | $53.50 | 2024-2025 | Arikayce, Brinsupri |
| Pfizer INC. | $47.77 | 2023-2025 | |
| Organogenesis INC. | $44.27 | 2021-2023 | Puraply |
| Melinta Therapeutics, LLC | $39.80 | 2025 | Rezzayo, Kimyrsa |
| Viiv Healthcare Company | $37.97 | 2025 | Apretude, Dovato |
| Cumberland Pharmaceuticals, INC. | $36.31 | 2025 | Vibativ |
| La Jolla Pharmaceutical Company | $29.70 | 2023 | Xerava |
| Invivyd INC | $18.44 | 2025 | Pemgarda |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $15.95 | 2024 | Rebyota |
| Celularity INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fazila Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.